1. Home
  2. BCRX vs TSHA Comparison

BCRX vs TSHA Comparison

Compare BCRX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

N/A

Current Price

$7.20

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$3.72

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCRX
TSHA
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.3B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
BCRX
TSHA
Price
$7.20
$3.72
Analyst Decision
Buy
Strong Buy
Analyst Count
11
13
Target Price
★ $20.45
$13.00
AVG Volume (30 Days)
★ 4.5M
2.5M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 381.40
5.56
EPS
N/A
★ N/A
Revenue
★ $25,186,000.00
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.71
$6,389.64
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 17.28
52 Week Low
$6.23
$3.46
52 Week High
$11.22
$7.30

Technical Indicators

Market Signals
Indicator
BCRX
TSHA
Relative Strength Index (RSI) 35.29 34.29
Support Level N/A $3.46
Resistance Level $8.83 $4.57
Average True Range (ATR) 0.37 0.28
MACD -0.05 -0.03
Stochastic Oscillator 0.87 11.29

Price Performance

Historical Comparison
BCRX
TSHA

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: